Gut microbiome changes and cancer immunotherapy outcomes associated with dietary interventions: a systematic review of preclinical and clinical evidence.

Publication date: Jul 08, 2025

Cancer patient’s survival has gradually improved due to immune checkpoint inhibitors (ICIs). Several studies showed a possible association between the intestinal microbiome and ICI efficacy. Strategies for modifying the composition of the gut microbiome encompass various dietary interventions, which may have distinct impacts on the outcomes of ICI-treated patients. In our systematic review, we explored how dietary habits correlate with therapeutic responses in cancer patients and cancer mouse models undergoing immunotherapy. A systematic review was conducted using search terms: “cancer”, “immunotherapy”, “diet”, and “microbiome”, from Medline, Web of Science, Scopus, and Cochrane Library databases. The outcomes in the clinical studies were overall response rate (ORR), overall survival (OS), or progression-free survival (PFS) in human studies. In mouse studies, change in tumor size was the endpoint. The comparator attributions were questionnaire-based dietary interventions. Nineteen articles met the inclusion criteria and were included in the review (6 prospective cohort studies, 1 cross-sectional observational study, and 12 mouse studies). A consistent association was observed between high (vs. low) fiber consumption and improved therapeutic response with a pooled odds ratio of 5. 79 when including all human prospective cohort studies. In mice, limited availability of methionine, cysteine, and low intake of leucine and glutamine was linked to reduced tumor progression. Combining ICIs with intermittent fasting or a fasting-mimicking diet significantly decreased tumor volume in mouse melanoma models. In humans, a higher relative abundance of short-chain fatty acid (SCFA) and lactic acid-producing bacteria-particularly Faecalibacterium prausnitzii and Akkermansia muciniphila-correlated with objective response rates (ORR). Similar microbiome alterations were observed in mouse models. Increased fiber intake enhanced ICI efficacy in mice by modulating the gut microbiome, primarily via elevated SCFA production-an effect also reflected in human studies. Intermittent fasting, high fiber, and low sugar consumption are significantly associated with better ICI outcomes. The studies revealed alterations in microbiota composition linked to diet, and these findings were confirmed in animal models, regarding the production of SCFAs and lactic acid, as well as an increase in Bacteroidota/Bacillota ratio and microbial diversity.

Open Access PDF

Concepts Keywords
Bacteroidota Cancer
Cancer Diet
Dietary Fiber intake
Improved Gut microbiome
Library Immunotherapy
Ketogenic diet

Semantics

Type Source Name
disease MESH cancer
drug DRUGBANK Methionine
drug DRUGBANK L-Cysteine
drug DRUGBANK L-Leucine
drug DRUGBANK L-Glutamine
disease MESH melanoma
pathway KEGG Melanoma
drug DRUGBANK Lactic Acid
drug DRUGBANK Tropicamide
pathway REACTOME Reproduction
pathway REACTOME Immune System
pathway REACTOME Metabolism
drug DRUGBANK Coenzyme M
drug DRUGBANK Trestolone
disease MESH glioma
pathway KEGG Glioma
disease MESH carcinoma
disease MESH lymphoma
disease MESH renal carcinoma
disease MESH coma
drug DRUGBANK Fenamole
disease MESH plant based diet
pathway REACTOME Fatty acids
drug DRUGBANK Inulin
drug DRUGBANK Pectin
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Fructose
drug DRUGBANK Ethanol
drug DRUGBANK Omega-3 fatty acids
drug DRUGBANK Icosapent
drug DRUGBANK Amino acids
drug DRUGBANK Indoleacetic acid
disease MESH immune tolerance
drug DRUGBANK Butyric Acid
pathway KEGG Tight junction
drug DRUGBANK Clotiazepam
disease MESH clinical relevance
disease MESH obesity
disease MESH metabolic syndrome
disease MESH Western diet
disease MESH glioblastoma
disease MESH colon cancer
disease MESH tic
disease MESH lung cancer
pathway KEGG Metabolic pathways
disease MESH noma
drug DRUGBANK Arachidonic Acid
drug DRUGBANK Pembrolizumab
drug DRUGBANK Carboxyamidotriazole
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH Infections
disease MESH ulcerative colitis
drug DRUGBANK Nivolumab
disease MESH Death
drug DRUGBANK Serine
drug DRUGBANK Glycine
disease MESH starvation
disease MESH esophageal cancer
disease MESH rectal cancer
drug DRUGBANK Ilex paraguariensis leaf
pathway KEGG Ferroptosis
drug DRUGBANK Corticosterone
disease MESH malnutrition
disease MESH gastrointestinal cancer

Original Article

(Visited 9 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *